Status:
COMPLETED
Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
Commercial ziprasidone capsules show a large increase in bioavailability with food. The formulation tested in this study aims to reduce or eliminate that increase.
Eligibility Criteria
Inclusion
- Healthy subjects
- Signed informed consent document
Exclusion
- Any significant physical or psychological disease
- Concomitant administration of other pharmaceuticals
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT00821444
Start Date
January 1 2009
End Date
March 1 2009
Last Update
February 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511-5473